FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Ajer Jeffrey Robert 2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [ BMRN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Chief Commercial Officer
(Last)         (First)         (Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
4/30/2020
(Street)
NOVATO, CA 94949
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  4/30/2020 (1)   A   V 338  A $62.586  63402  D   
Common Stock  6/19/2020 (2)   M    15000  A $63.100  78402  D   
Common Stock  6/19/2020 (2)   S    15000  D $124.00  63402  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy Common Stock)  $63.100  6/19/2020 (2)   M        15000   12/4/2014  6/3/2024  Common Stock  15000  $0  15700.000 (3) D   

Explanation of Responses:
(1)  Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan.
(2)  Trade made pursuant to a 10b5-1 plan executed on December 20, 2019.
(3)  Reflects the number of options outstanding after the transactions from this specific stock option grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ajer Jeffrey Robert
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949


EVP, Chief Commercial Officer

Signatures
/s/ Eric Fleekop, Attorney-in-Fact 6/23/2020
**Signature of Reporting Person Date
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more BioMarin Pharmaceutical Charts.